2 results
Suicide Deaths Before and During the COVID 19 Pandemic
- R. Rossom, R. Penfold, A. Owen-Smith, G. Simon, B. Ahmedani
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, p. S88
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
With stressors that are often associated with suicide increasing during the coronavirus disease 2019 (COVID-19) pandemic, there has been concern that suicide mortality rates may also be increasing. Our objective was to determine whether suicide mortality rates increased during the COVID-19 pandemic.
With stressors that are often associated with suicideincreasing during the coronavirus disease 2019 (COVID-19) pandemic,there has been concern that suicide mortality rates may alsobe increasing.
ObjectivesOur objective was to determine whether suicidemortality rates increased during the COVID-19 pandemic.
MethodsWe conducted an interrupted time-series study using data from January 2019 through December 2020 from 2 large integrated health care systems. The population at risk included all patients or individuals enrolled in a health plan at HealthPartners in Minnesota or Henry Ford Health in Michigan. The primary outcome was change in suicide mortality rates, expressed as annualized crude rates of suicide death per 100,000 people in 10 months following the start of the pandemic in March 2020 compared with the 14 months prior. We conducted an interrupted time-series study using data fromJanuary 2019 through December 2020 from 2 large integrated health care systems. The population at risk included all patients or individuals enrolledin a health plan at HealthPartners in Minnesota or Henry Ford HealthSystem in Michigan. The primary outcome was change in suicide mortality rates, expressed as annualized crude rates of suicide death per 100,000 people in 10 months following the start of the pandemic in March2020 compared with the 14 months prior.
ResultsThere were 6,434,675 people at risk in the sample, with 55% women and a diverse sample across ages, race/ethnicity, and insurance type. From January 2019 through February 2020, there was a slow increase in the suicide mortality rate, with rates then decreasing by 0.45 per 100,000 people per month from March 2020 through December 2020 (SE= 0.19, P=0.03). There were 6,434,675 people at risk in the sample, with 55% women and a diverse sample across ages, race/ethnicity, and insurance type. From January 2019 through February 2020, there was a slow increase in the suicide mortality rate, with rates then decreasing by 0.45 per 100,000 people per month from March 2020 through December 2020 (SE= 0.19, P=0.03).
ConclusionsOverall suicide mortality rates did not increase with the pandemic, and in fact slightly declined from March to December 2020. Our findings should be confirmed across other settings and, when available, using final adjudicated state mortality data. Overall suicide mortality rates did not increase with the pandemic, and in fact slightly declined from March to December 2020. Our findings should be confirmed across other settings and,when available, using final adjudicated state mortality data.
Disclosure of InterestNone Declared
Pragmatic Clinical Trial to Improve Screening and Treatment for Opioid Use Disorder in Primary Care
- R. Rossom
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, p. S568
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
Opioid-related deaths continue to rise in the U.S. A clinical decision support (CDS) system to help primary care clinicians (PCCs) identify and treat patients with opioid use disorder (OUD) could help address this crisis.
ObjectivesTo implement and test an OUD-CDS system in three health systems for the diagnosis and treatment of OUD in 90 primary care clinics.
MethodsIn this cluster-randomized trial, primary care clinics in three healthcare systems were randomized to receive or not receive access to an OUD-CDS system. The OUD-CDS system alerts PCCs and patients to elevated risk of OUD and supports OUD screening and treatment. It includes guidance on OUD screening and diagnosis, treatment selection, starting and maintaining patients on buprenorphine for waivered clinicians, and screening for common comorbid conditions. The primary study outcome is, of patients at high risk for OUD, the percentage receiving an OUD diagnosis within 30 days of index visit. Additional outcomes are, of patients at high risk for or with a diagnosis of OUD, (a) the percentage receiving a naloxone prescription, or (b) the percentage receiving a medication for OUD (MOUD) prescription or referral to specialty care within 30 days of an index visit, and (c) total days covered by a MOUD prescription within 90 days of an index visit.
ResultsThe intervention started in April 2021 and continues through December 2023, with successful implementatio and uptake. PCCs and patients in 90 clinics are included; study results are expected in 2024.
Image:
Image 2:
Image 3:
ConclusionsIf effective, this OUD-CDS intervention could improve screening of at-risk patients and rates of OUD treatment for people with OUD, a significant step in decreasing the morbidity and mortality associated with OUD.
Disclosure of InterestNone Declared
![](/core/cambridge-core/public/images/lazy-loader.gif)